NeuBase Therapeutics to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5th
September 28, 2020 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Sept. 28, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class...
NeuBase Therapeutics to Present at the Myotonic Dystrophy Foundation 2020 Virtual Conference
September 17, 2020 08:30 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Sept. 17, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class...
NeuBase Therapeutics to Present at Upcoming Investor Conferences in September 2020
September 08, 2020 08:00 ET
|
NeuBase Therapeutics, Inc.
22nd Annual H.C. Wainwright Global Investor Conference presentation at 1:30 p.m. ET on September 16THOppenheimer Fall Healthcare LifeSciences & Medtech Summit Fireside Chat at 10:00 a.m. ET on...
NeuBase Therapeutics Reports Financial Results for the Third Fiscal Quarter of 2020
August 13, 2020 16:01 ET
|
NeuBase Therapeutics, Inc.
Strong Pharmacokinetic and Pharmacodynamic Data Presented in March Validate Platform and Position Company for Scalable Output of Synthetic Precision Genetic Medicines Company Continues to Progress...
NeuBase Therapeutics to Present at the BTIG Virtual Biotechnology Conference on Tuesday, August 11th
July 30, 2020 16:01 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, July 30, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense oligonucleotide...
NeuBase Therapeutics Strengthens Senior Management Team with Appointment of Industry Veteran William Mann, Ph.D., MBA as Chief Operating Officer
July 28, 2020 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, July 28, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing next-generation antisense oligonucleotide...
NeuBase Therapeutics Added to Russell 3000® and Russell Microcap® Indexes
June 29, 2020 09:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, June 29, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense oligonucleotide...
NeuBase Therapeutics Reports Financial Results for the Second Fiscal Quarter of 2020
May 14, 2020 16:05 ET
|
NeuBase Therapeutics, Inc.
- - -Announced positive preclinical data that validates the key advantages of the proprietary NeuBase peptide-nucleic acid antisense oligonucleotide (PATrOL™) platform- - -Completed a public offering...
NeuBase Therapeutics to Present at Upcoming Investor Conferences in May 2020
May 11, 2020 08:00 ET
|
NeuBase Therapeutics, Inc.
6th Annual SunTrust Robinson Humphrey Life Sciences Summit Virtual Series Fireside Chat at 2:30 p.m. ET on May 15THRBC Capital Markets 2020 Global Healthcare Conference presentation at 1:20 p.m. ET on...
NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 30, 2020 16:05 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, April 30, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), a preclinical-stage biotechnology company focused on developing next generation therapies to treat rare...